# Hematopoietic Stem Cell Transplant for Sickle Cell Disease

> **NCT02065596** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia
- SCD

## Interventions

- **DRUG:** Fludarabine
- **PROCEDURE:** Hematopoietic Stem Cell Transplant (HSCT)

## Key facts

- **NCT ID:** NCT02065596
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-19
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-17
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065596, "Hematopoietic Stem Cell Transplant for Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02065596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*